Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA:688553)

Market Cap	8.06B +33.2%
Revenue (ttm)	984.29M -12.1%
Net Income	47.23M -83.0%
EPS	0.11 -83.1%
Shares Out	421.46M
PE Ratio	171.78
Forward PE	n/a
Dividend	0.46 (2.48%)
Ex-Dividend Date	Jun 13, 2025

Volume	4,271,871
Average Volume	6,983,955
Open	18.71
Previous Close	18.67
Day's Range	18.71 - 19.26
52-Week Range	13.02 - 28.28
Beta	0.36
RSI	39.20
Earnings Date	Apr 25, 2026

About SHA:688553

Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. It also offers moroxydine sodium chloride, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 1,331
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688553

Financial Performance

In 2024, SHA:688553's revenue was 1.09 billion, an increase of 18.05% compared to the previous year's 927.08 million. Earnings were 325.39 million, an increase of 132.78%.